Developments in post-marketing comparative effectiveness research

Clinical Pharmacology and Therapeutics

Volumn 82, Issue 2, 2007, Pages 143-156

  Schneeweiss, S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL; THIAZIDE DIURETIC AGENT;

CLINICAL PRACTICE; CONFOUNDING VARIABLE; DATA BASE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MARKETING; DRUG SAFETY; DRUG USE; HEALTH CARE PERSONNEL; HEALTH CARE UTILIZATION; HUMAN; MEDICAL INFORMATION SYSTEM; PHYSICIAN; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS; REVIEW; SENSITIVITY ANALYSIS; STRATIFICATION; TREATMENT OUTCOME; VALIDITY;

CLINICAL TRIALS; DRUG UTILIZATION; HUMANS; MODELS, THEORETICAL; PHARMACOEPIDEMIOLOGY; PRODUCT SURVEILLANCE, POSTMARKETING; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 34447547659     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/sj.clpt.6100249     Document Type: Review

References (88)

1. Cochrane, A. Effectiveness and Efficiency: Random Reflection on Health Services, (Nuffiled Provincial Trust, London, 1972).
2. van Luijn, J.C.F., Gribnau, F.W.J. & Leufkens, H.G.M. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization. Br. J. Clin. Pharm. 63, 159-162 (2007).
3. Pisano, D.J. & Mantus, D. FDA Regulatory Affairs: A Guide for Prescription Drugs, Medical Devices, and Biologics, (CRC Press, Boca Rotan, FL, 2004).
4. Song, F., Altman, D.G., Glenny, A.M. & Deeks, J.J. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. Br. Med. J. 326, 472-477 (2003).
5. Bucher, H.C., Guyatt, G.H., Griffith, L.E. & Walter, S.D. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J. Clin. Epidemiol. 50, 683-691 (1997).
6. Lumley, T. Network meta-analysis for indirect treatment comparisons. Stat. Med. 21, 2313-2324 (2002).
7. Lu, G. & Ades, A.E. Combination of direct and indirect evidence in mixed treatment comparisons. Stat. Med. 23, 3105-3124 (2004).
8. Schneeweiss, S. & Avorn, J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J. Clin. Epidemiol. 58, 323-337 (2005).
9. Halpern, S.D., Ubel, P.A., Berlin, J.A., Townsend, R.R. & Asch, D.A. Physicians' preferences for active-controlled versus placebo-controlled trials of new antihypertensive drugs. J. Gen. Int. Med. 17, 689-695 (2002).
10. Schneeweiss, S. Reference drug programs: effectiveness and policy implications. Health Policy 81, 17-28 (2007).
11. Clancy, C. Getting to "smart" health care comparative effectiveness research is a key component of, but tightly linked with, health care delivery in the information age. Health Aff. w589-w592 (2006).
12. Strom, B.L. & Carson, J.L. Use of automated databases for pharmacoepidemiology research. Epidemiol. Rev. 12, 87-106 (1990).
13. Selby, J.V. Linking automated databases for research in managed care settings. Ann. Intern. Med. 127, 719-724 (1997).
14. Platt, R. The future of drug safety - challenges for FDA. Presented at the Institute of Medicine Forum, Washington, DC (2007).
15. Rodriguez, E.M., Staffa, J.A. & Graham, D.J. The role of databases in drug postmarketing surveillance. Pharmacoepidemiol. Drug Saf. 10, 407-410 (2001).
16. Schneeweiss, S. Understanding secondary databases (Commentary). J. Clin. Epidemiol. (2007, in press).
17. Schneeweiss, S., Glynn, R.J., Avorn, J. & Solomon, D.H. A Medicare database review found that physician preferences increasingly outweighed patient characteristics as determinants of first-time prescriptions for cox-2 inhibitors. J. Clin. Epidemiol. 58, 98-102 (2005).
18. Petri, H. & Urquhart, J. Channeling bias in the interpretation of drug effects. Stat. Med. 10, 577-581 (1991).
19. Walker, A.M. Confounding by indication. Epidemiology 7, 335-336 (1996).
20. MacDonald, T.M., Morant, S.V., Goldstein, J.L., Burke, T.A. & Pettitt, D. Channelling bias and the incidence of gastrointestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 52, 1265-1270 (2003).
21. Moore, R.A., Derry, S., Makinson, G.T. & MacQuay, H.J. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports. Arthritis. Res. Ther. 7, R644-R665 (2005).
22. Watson, D.J., Harper, S.E., Zhao, P.L., Quan, H., Bolognese, J.A. & Simon, T.J. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) inhibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch. Intern. Med. 160, 2998-3003 (2000).
23. Eisen, G.M., Goldstein, J.L., Hanna, D.B. & Rublee, D.A. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment. Pharmacol. Ther. 21, 591-598 (2005).
24. McMahon, A.D. Observation and experiment with the efficacy of drugs: a warning example from a cohort of nonsteroidal anti-inflammatory and ulcer-healing drug users. Am. J. Epidemiol. 154, 557-562 (2001).
25. Laporte, J.R., Ibanez, L., Vidal, X., Vendrell, L. & Leone, R. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 27, 411-420 (2004).
26. Greenland, S., Pearl, J. & Robins, J.M. Causal diagrams for epidemiologic research. Epidemiology 10, 37-48 (1999).
27. Vandenbroucke, J.P. When are observational studies as credible as randomized trials? Lancet 363, 1728-1731 (2004).
28. Wolfe, F., Flowers, N., Burke, T.A., Arguelles, L.M. & Pettitt, D. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J. Rheumatol. 29, 1015-1022 (2002).
29. Sorensen, H.T., Lash, T.L. & Rothman, K.J. Beyond randomized controlled trials: a critical comparison of trials with non-randomized studies. Hepatology 44, 1075-1082 (2006).
30. Rubin, D.B. Estimating causal effects of treatments in randomized and nonrandomized studies. J. Edu. Psychol. 66, 688-701 (1974).
31. Sebaldt, R.J., Petrie, A., Goldsmith, C.H. & Marentette, M.A. Appropriateness of NSAID and Coxib prescribing for patients with osteoarthritis by primary care physicians in Ontario: results from the CANOAR study. Am. J. Manag. Care 10, 742-750 (2004).
32. Schneeweiss, S., Glynn, R.J., Tsai, E.H., Avorn, J. & Solomon, D.H. Adjusting for unmeasured confounders in pharmacoepidemiologic claims data using external information: the example of COX2 inhibitions and myocardial infarction. Epidemiology 16, 17-24 (2005).
33. Brookhart, M.A., Solomon, D.H., Wang, P., Glynn, R.J., Avorn, J. & Schneeweiss, S. Explained variation in a model of therapeutic decision making is partitioned across patient, physician, and clinic factors. J. Clin. Epidemiol. 59, 18-25 (2006).
34. Schneeweiss, S., Solomon, D.H., Wang, P.S. & Brookhart, M.A. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective COX-2 inhibitors and non-selective NSAIDs: an instrumental variable analysis. Arthritis Rheum. 54, 3390-3398 (2006).
35. Schneeweiss, S. et al. Restriction in pharmacoepidemiologic database studies of elderly to approximate randomized trial results. Med. Care (2007) (in press).
36. Ray, W.A. Evaluating medication effects outside of clinical trials: new-user designs. Am. J. Epidemiol. 158, 915-920 (2003).
37. Glynn, R.J., Knight, E.L., Levin, R. & Avorn, J. Paradoxical relations of drug treatment with mortality in older persons. Epidemiology 12, 682-689 (2001).
38. Glynn, R.J., Schneeweiss, S., Wang, P., Levin, R. & Avorn, J. Selective prescribing can lead to over-estimation of the benefits of lipid-lowering drugs. J. Clin. Epidemiol. 59, 819-828 (2006).
39. Stürmer, T., Rothman, K.J. & Glynn, R.J. Insights into different results from different causal contrasts in the presence of effect-measure modification. Pharmacoepidemiol. Drug Saf. 15, 698-709 (2006).
40. Benner, J.S., Glynn, R.J., Mogun, H., Neumann, P.J., Weinstein, M.C. & Avorn, J. Long-term persistence in use of statin therapy in elderly patients. JAMA 288, 455-461 (2002).
41. Pablos-Mendez, A., Barr, R.G. & Shea, S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 279, 222-225 (1998).
42. Rothwell, P.M. Subgroup analysis in randomized controlled trials: importance, indications, and interpretation. Lancet 365, 176-186 (2005).
43. Maclure, M. The case-crossover design: a method for studying transient effects on the risk of acute events. Am. J. Epidemiol. 133, 144-153 (1991).
44. Hallas, J. Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 7, 478-484 (1996).
45. Hubbard, R., Farrington, P., Smith, C., Smeeth, L. & Tattersfield, A. Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am. J. Epidemiol. 158, 77-84 (2003).
46. Schneeweiss, S. & Wang, P. Association between SSRI use and hip fractures and the effect of residual confounding bias in claims database studies. J. Clin. Psychopharmacol. 24, 632-638 (2004).
47. Vines, S.K. & Farrington, C.P. Within-subject exposure dependency in case-crossover studies. Stat. Med. 20, 3039-3049 (2001).
48. Wang, P.S., Schneeweiss, S., Glynn, R.J., Mogun, H. & Avorn, J. Use of the case-crossover design to study prolonged drug exposures and insidious outcomes. Ann. Epidemiol. 14, 296-303 (2004).
49. Suissa, S. The case-time-control design. Epidemiology 6, 248-253 (1995).
50. Suissa, S. The case-time-control design: further assumptions and conditions. Epidemiology 9, 441-445 (1998).
51. Roblin, D.W. et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much? Med. Care 43, 951-959 (2005).
52. Schneeweiss, S., Seeger, J., Maclure, M., Wang, P., Avorn, J. & Glynn, R.J. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am. J. Epidemiol. 154, 854-864 (2001).
53. Wooldridge, J.M. Econometric Analysis of Cross Section and Panel Data, (MIT Press, Cambridge, MA, 2002).
54. Peduzzi, P., Concato, J., Kemper, E., Holford, T.R. & Feinstein, A.R. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 49, 1373-1379 (1996).
55. Stürmer, T., Joshi, M., Glynn, R.J., Avorn, J., Rothman, K.J. & Schneeweiss, S. A review of the application of propensity score methods yielded increasing use, advantages in specific settings, but not substantially different estimates compared with conventional multivariable methods. J. Clin. Epidemiol. 59, 437-447 (2006).
56. Rosenbaum, P.R. & Rubin, D.B. The central role of the propensity score in observational studies for causal effects. Biometrika 70, 41-55 (1983).
57. Miettinen, O.S. Stratification by a multivariate confounder score. Am. J. Epidemiol. 104, 609-620 (1976).
58. Stürmer, T., Schneeweiss, S., Brookhart, M.A., Rothman, K.J., Avorn, J. & Glynn, R.J. Analytic strategies to adjust confounding bias using exposure propensity scores and disease risk scores: nonsteroidal anti-inflammatory drugs and short-term mortality in the elderly. Am. J. Epidemiol. 161, 891-898 (2005).
59. Cepeda, M.S., Boston, R., Farrar, J.T. & Strom, B.L. Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am. J. Epidemiol. 158, 280-287 (2003).
60. Rothman, K.J. & Greenland, S. Modern Epidemiology, 2nd edn. (Lippincott Williams & Wilkins, Philadelphia, PA, 1998).
61. Stürmer, T. et al. Range restriction may reduce bias in stratified propensity score analyses: simulation results based on uniform effects. Pharmacoepidemiol. Drug Saf. 15, S269-S270 (2006).
62. Kurth, T. et al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am. J. Epidemiol. 163, 262-270 (2006).
63. Schneeweiss, S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol. Drug Saf. 15, 291-303 (2006).
64. Schneeweiss, S. & Wang, P. Claims data studies of sedative-hypnotics and hip fractures in the elderly: exploring residual confounding using survey information. J. Am. Geriatr. Soc. 53, 948-954 (2005).
65. Stürmer, T., Schneeweiss, S., Avorn, J. & Glynn, R.J. Correcting effect estimates for unmeasured confounding in cohort studies with validation studies using propensity score calibration. Am. J. Epidemiol. 162, 279-289 (2005).
66. Sturmer, T., Schneeweiss, S., Rothman, K.J., Avorn, J. & Glynn, R.J. Performance of propensity score calibration - a simulation study. Am. J. Epidemiol. 165, 1110-1118 (2007).
67. Collet, J.P., Schaubel, D., Hanley, J., Sharpe, C. & Boivin, J.F. Controlling confounding when studying large pharmacoepidemiologic databases: a case study of the two-stage sampling design. Epidemiology 9, 309-315 (1998).
68. Walker, A.M. Anamorphic analysis: sampling and estimation for covariate effects when both exposure and disease are known. Biometrics 38, 1025-1032 (1982).
69. Cain, K.C. & Breslow, N.E. Logistic regression analysis and efficient design for two-stage studies. Am. J. Epidemiol. 128, 1198-1206 (1988).
70. Flanders, W.D. & Greenland, S. Analytic methods for two-stage case-control studies and other stratified designs. Stat. Med. 10, 739-747 (1991).
71. Bowden, R.J. & Turkington, D.A. Instrumental Variables, (Cambridge University Press, Cambridge, UK, 1984).
72. Angrist, J.D., Imbens, G.W. & Rubin, D.B. Identification of causal effects using instrumental variables. J. Am. Stat. Soc. 91, 444-455 (1996).
73. Angrist, J.D. & Krueger, A.B. Instrumental variables and the search for identification: from supply and demand to natural experiments. J. Econ. Perspect. 15(Fall): 69-85 (2001).
74. Murray, M.P. Avoiding invalid instruments and coping with weak instruments. J. Econ. Perspect. 20, 111-132 (2006).
75. Brookhart, M.A., Wang, P.S., Solomon, D.H. & Schneeweiss, S. Evaluating short-term drug effects in claims databases using physician-specific prescribing preferences as an instrumental variable. Epidemiology 17, 268-275 (2006).
76. Greene, W.H. In Econometric Analysis, 3rd edn., 740-742 (Prentice Hall, Upper Saddle River, NJ, 1997).
77. West, S.L., Strom, B.L. & Poole, C. Validity of pharmacoepidemiology drug and diagnosis data. In Pharmacoepidemiology, 3rd edn. (ed. Strom, B.L.), 668 (Wiley, Chichester, 2000).
78. Schlesselman, J.J. Assessing effects of confounding variables. Am. J. Epidemiol. 108, 3-8 (1978).
79. Walker, A.M. Newer oral contraceptives and the risk of venous thromboembolism. Contraception 57, 169-181 (1998).
80. Wang, P.S., Bohn, R.L., Glynn, R.J., Mogun, H. & Avorn, J. Zolpidem use and hip fractures in older people. J. Am. Geriatr. Soc. 49, 1685-1690 (2001).
81. Gail, M.H., Wacholder, S. & Lubin, J.H. Indirect corrections for confounding under multiplicative and additive risk models. Am. J. Ind. Med. 13, 119-130 (1988).
82. Psaty, B.M. et al. Assessment and control for confounding by indication in observational studies. J. Am. Geriatr. Soc. 47, 749-754 (1999).
83. Strom, B.L., Miettinen, O.S. & Melmon, K.L. Postmarketing studies of drug efficacy: When must they be randomized. Clin. Pharmacol. Ther. 34, 1-7 (1983).
84. ALLHAT Working Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).
85. Schneider, L.S., et al. & CATIE-AD Study Group Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N. Engl. J. Med. 355, 1525-1538 (2006).
86. Pilote, L., Abrahamowicz, M., Rodrigues, E., Eisenberg, M.J. & Rahme, E. Mortality rates in elderly patients who take different angiotensin- converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann. Intern. Med. 141, 102-112 (2004).
87. Wang, P.S. et al. Risk of death in elderly users of conventional vs atypical antipsychotic medications. N. Engl. J. Med. 353, 2335-2341 (2005).
88. Solomon, D.H. Selective cyclooxygenase 2 inhibitors and cardiovascular events. Arthritis Rheum. 52, 1968-1978 (2005).